Association between interleukin 17/interleukin 17 receptor gene polymorphisms and papillary thyroid cancer in Korean population

Cytokine

Volumn 71, Issue 2, 2015, Pages 283-288

  Lee, Young Chan ^a   Chung, Joo Ho ^a   Kim, Su Kang ^a   Rhee, Sang Youl ^a   Chon, Suk ^a   Oh, Seung Joon ^a   Hong, Il Ki ^a   Eun, Young Gyu ^a  

^a Kyung Hee University Hospital   (South Korea)

Author keywords

Interleukin 17; Polymorphism; Receptors; Single nucleotide; Thyroid neoplasm

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR;

ADULT; ARTICLE; CANCER LOCALIZATION; CANCER SIZE; CARCINOGENESIS; CLINICAL FEATURE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENE LOCATION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; IL17 GENE; IL17A GENE; IL17R GENE; IL17RA GENE; IL17RB GENE; KOREAN (PEOPLE); LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROTEIN FUNCTION; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; THYROID CARCINOMA; AGED; ALLELE; CASE CONTROL STUDY; COMPUTER PROGRAM; ETHNOLOGY; GENETIC PREDISPOSITION; GENETICS; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; RISK; SOUTH KOREA; THYROID TUMOR;

ADULT; AGED; ALLELES; BASE SEQUENCE; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-17; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, INTERLEUKIN-17; REPUBLIC OF KOREA; SOFTWARE; THYROID NEOPLASMS;

EID: 84916881375     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.11.011     Document Type: Article

References (33)

1. Hundahl S.A., Fleming I.D., Fremgen A.M., Menck H.R. A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 1998, 83:2638-2648. [see comments].
2. Leenhardt L., Grosclaude P., Cherie-Challine L. Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid 2004, 14:1056-1060.
3. Sprague B.L., Warren Andersen S., Trentham-Dietz A. Thyroid cancer incidence and socioeconomic indicators of health care access. Cancer Causes Control 2008, 19:585-593.
4. Vlajinac H.D., Adanja B.J., Zivaljevic V.R., Jankovic R.R., Dzodic R.R., Jovanovic D.D. Malignant tumors in families of thyroid cancer patients. Acta Oncol 1997, 36:477-481.
5. Pal T., Vogl F.D., Chappuis P.O., Tsang R., Brierley J., Renard H., et al. Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study. J Clin Endocrinol Metab 2001, 86:5307-5312.
6. Frich L., Glattre E., Akslen L.A. Familial occurrence of nonmedullary thyroid cancer: a population-based study of 5673 first-degree relatives of thyroid cancer patients from Norway. Cancer Epidemiol Biomarkers Prev 2001, 10:113-117.
7. Guarino V., Castellone M.D., Avilla E., Melillo R.M. Thyroid cancer and inflammation. Mol Cell Endocrinol 2010, 321:94-102.
8. Bozec A., Lassalle S., Hofman V., Ilie M., Santini J., Hofman P. The thyroid gland: a crossroad in inflammation-induced carcinoma? An ongoing debate with new therapeutic potential. Curr Med Chem 2010, 17:3449-3461.
9. Plantinga T.S., Costantini I., Heinhuis B., Huijbers A., Semango G., Kusters B., et al. A promoter polymorphism in human interleukin-32 modulates its expression and influences the risk and the outcome of epithelial cell-derived thyroid carcinoma. Carcinogenesis 2013, 34:1529-1535.
10. Liotti F., Visciano C., Melillo R.M. Inflammation in thyroid oncogenesis. Am J Cancer Res 2012, 2:286-297.
11. Castellanos-Rubio A., Santin I., Irastorza I., Castano L., Carlos Vitoria J., Ramon Bilbao J. TH17 (and TH1) signatures of intestinal biopsies of CD patients in response to gliadin. Autoimmunity 2009, 42:69-73.
12. Miyahara Y., Odunsi K., Chen W., Peng G., Matsuzaki J., Wang R.F. Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci USA 2008, 105:15505-15510.
13. Su X., Ye J., Hsueh E.C., Zhang Y., Hoft D.F., Peng G. Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol 2010, 184:1630-1641.
14. Kolls J.K., Linden A. Interleukin-17 family members and inflammation. Immunity 2004, 21:467-476.
15. Kawaguchi M., Adachi M., Oda N., Kokubu F., Huang S.K. IL-17 cytokine family. J Allergy Clin Immunol 2004, 114:1265-1273. quiz 74.
16. Kato T., Furumoto H., Ogura T., Onishi Y., Irahara M., Yamano S., et al. Expression of IL-17 mRNA in ovarian cancer. Biochem Biophys Res Commun 2001, 282:735-738.
17. Zhu X., Mulcahy L.A., Mohammed R.A., Lee A.H., Franks H.A., Kilpatrick L., et al. IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res 2008, 10:R95.
18. Zhang Y., Ma D., Tian Y., Wang X., Qiao Y., Cui B. The imbalance of Th17/Treg in patients with uterine cervical cancer. Clin Chim Acta 2011, 412:894-900.
19. Numasaki M., Lotze M.T., Sasaki H. Interleukin-17 augments tumor necrosis factor-alpha-induced elaboration of proangiogenic factors from fibroblasts. Immunol Lett 2004, 93:39-43.
20. Wang L., Jiang Y., Zhang Y., Wang Y., Huang S., Wang Z., et al. Association analysis of IL-17A and IL-17F polymorphisms in Chinese Han women with breast cancer. PLoS ONE 2012, 7:e34400.
21. Quan Y., Zhou B., Wang Y., Duan R., Wang K., Gao Q., et al. Association between IL17 polymorphisms and risk of cervical cancer in Chinese women. Clin Dev Immunol 2012, 2012:258293.
22. Weaver C.T., Hatton R.D., Mangan P.R., Harrington L.E. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007, 25:821-852.
23. McGeachy M.J., Cua D.J. Th17 cell differentiation: the long and winding road. Immunity 2008, 28:445-453.
24. Yao Z., Fanslow W.C., Seldin M.F., Rousseau A.M., Painter S.L., Comeau M.R., et al. Herpesvirus saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. J Immunol 2011, 187:4392-4402.
25. Silva-Santos B. Promoting angiogenesis within the tumor microenvironment: the secret life of murine lymphoid IL-17-producing gammadelta T cells. Eur J Immunol 2010, 40:1873-1876.
26. Wakita D., Sumida K., Iwakura Y., Nishikawa H., Ohkuri T., Chamoto K., et al. Tumor-infiltrating IL-17-producing gammadelta T cells support the progression of tumor by promoting angiogenesis. Eur J Immunol 2010, 40:1927-1937.
27. Takahashi H., Numasaki M., Lotze M.T., Sasaki H. Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells. Immunol Lett 2005, 98:189-193.
28. Numasaki M., Watanabe M., Suzuki T., Takahashi H., Nakamura A., McAllister F., et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 2005, 175:6177-6189.
29. Wang L., Yi T., Kortylewski M., Pardoll D.M., Zeng D., Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 2009, 206:1457-1464.
30. Lee J.J., Chang Y.L., Lai W.L., Ko J.Y., Kuo M.Y., Chiang C.P., et al. Increased prevalence of interleukin-17-producing CD4(+) tumor infiltrating lymphocytes in human oral squamous cell carcinoma. Head Neck 2011, 33:1301-1308.
31. Shibata T., Tahara T., Hirata I., Arisawa T. Genetic polymorphism of interleukin-17A and -17F genes in gastric carcinogenesis. Hum Immunol 2009, 70:547-551.
32. Pacini F., Elisei R., Capezzone M., Miccoli P., Molinaro E., Basolo F., et al. Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients. Thyroid 2001, 11:877-881.
33. Miccoli P., Minuto M.N., Ugolini C., Panicucci E., Berti P., Massi M., et al. Intrathyroidal differentiated thyroid carcinoma: tumor size-based surgical concepts. World J Surg 2007, 31:888-894.